Vol. 19 No. 4-2 (2015): Cell Technologies in Cardiology (Special Issue)
REVIEWS

Modeling of inherited cardiomyopathies based on human differentiated induced pluripotent stem cells derivatives

PDF (Русский)
  • D. Baizigitov,
  • S. Medvedev,
  • E. Dement'eva,
  • E. Pokushalov,
  • S. Zakiyan
D. Baizigitov
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
S. Medvedev
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
E. Dement'eva
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
E. Pokushalov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
S. Zakiyan
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2015-4-2-95-103

Published 2016-01-14

Keywords

  • IPSC,
  • cardiomyopathy,
  • disease modeling

How to Cite

Baizigitov, D., Medvedev, S., Dement’eva, E., Pokushalov, E., & Zakiyan, S. (2016). Modeling of inherited cardiomyopathies based on human differentiated induced pluripotent stem cells derivatives. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(4-2), 95–103. https://doi.org/10.21688/1681-3472-2015-4-2-95-103

Copyright (c) 2016 Baizigitov D.R., Medvedev S.P., Dement'eva E.V., Pokushalov E.A., Zakiyan S.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

One of the obstacles on the way to a better understanding of the pathogenesis of cardiomyopathies has been unavailability of tissue samples from the heart in the early stages of the disease. This has been changed with the emergence of patient-specific induced pluripotent stem cells (iPSC), from which cardiomyocytes in vitro can be derived. The feature of iPSC technology is that given the effects of thousands of individual gene variants, a phenotype of differentiated derivatives of these cells will provide more information about a specific disease of the patient than by simple genotyping. This article summarizes what is known about the models of cardiomyopathies in vitro, with an emphasis on identifying the molecular and cellular pathogenesis mechanisms, treatment and testing of new drugs.

PDF (Русский)

References

  1. Okita K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A., Goshima N., Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells // Stem Cells. 2013. Vol. 31. № 3. P. 458–66.
  2. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors // Cell. 2006. Vol. 126. № 4. P. 663–76.
  3. Doherty K.R., Talbert D.R., Trusk P.B., Moran D.M., Shell S.A., Bacus S. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types // Toxicol. Appl. Pharmacol. 2015. Vol. 285. № 1. P. 51–60.
  4. Gieseck R.L. 3rd, Vallier L., Hannan N.R. Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling // Methods Mol. Biol. 2015. Vol. 1250. P. 123–42.
  5. Shinde V., Klima S., Sureshkumar P.S., Meganathan K., Jagtap S., Rempel E., Rahnenführer J., Hengstler J.G., Waldmann T., Hescheler J., Leist M., Sachinidis A. Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation // J. Vis. Exp. 2015. Vol. 100. P. e52333.
  6. Eschenhagen T., Mummery C., Knollmann B.C. Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes // Cardiovasc. Res. 2015. Vol. 105. № 4. P. 424–38.
  7. Itzhaki I., Maizels L., Huber I, Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., Boulos M., Gepstein L. Modeling the Long QT Syndrome with Human Induced Pluripotent Stem Cells // Circulation. 2010. Vol. 122. № 21. P. 225–9.
  8. Ma D.R., Wei H.M., Lu J., Loh L.J., Islam O., Liew R., Shim W., Cook S.A. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes // Stem Cell Research & Therapy. 2015. Vol. 6. P. 39.
  9. Ma D.R., Wei H.M., Zhao Y.X., Lu J., Li G., Sahib N.B., Tan T.H., Wong K.Y., Shim W., Wong P., Cook S.A., Liew R. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells // International Journal of Cardiology. 2013. Vol. 168. № 6. P. 5277–86.
  10. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., and Dolmetsch R.E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome // Nature. 2011. Vol. 471. № 7337. P. 230–4.
  11. Ma D., Wei H., Lu J., Ho S., Zhang G., Sun X., Oh Y., Tan S.H., Ng M.L., Shim W., Wong P., Liew R. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy // Eur. Heart J. 2013. Vol. 34. №15. P. 1122–33.
  12. Wen J.Y., Wei C.Y., Shah K., Wong J., Wang C., Chen H.S. Maturation-Based Model of Arrhythmogenic Right Ventricular Dysplasia Using Patient-Specific Induced Pluripotent Stem Cells // Circ. J. 2015. Vol. 79. № 7. P. 1402–8.
  13. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., Abilez O.J., Navarrete E.G., Hu S., Wang L., Lee A., Pavlovic A., Lin S., Chen R., Hajjar R.J., Snyder M.P., Dolmetsch RE., Butte M.J., Ashley E.A., Longaker M.T., Robbins R.C., Wu J.C. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy // Sci. Transl. Med. 2012. Vol. 4. № 130. P. 130ra47.
  14. Tse H.F., Ho J.C., Choi S.W., Lee Y.K., Butler A.W., Ng K.M., Siu C.W., Simpson M.A., Lai W.H., Chan Y.C., Au K.W., Zhang J., Lay K.W., Esteban M.A., Nicholls J.M., Colman A., Sham P.C. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing // Hum. Mol. Genet. 2013. Vol. 22. № 7. P. 1395–403.
  15. Han L., Li Y., Tchao J., Kaplan A.D., Lin B., Li Y., Mich-Basso J., Lis A., Hassan N., London B., Bett G.C., Tobita K., Rasmusson R.L., Yang L. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells // Cardiovasc. Res. 2014. Vol. 104. № 2. P. 258–69.
  16. Lan F., Lee A.S., Liang P., Sanchez-Freire V., Nguyen P.K., Wang L., Han L., Yen M., Wang Y., Sun N., Abilez O.J., Hu S., Ebert A.D., Navarrete E.G., Simmons C.S., Wheeler M., Pruitt B., Lewis R., Yamaguchi Y., Ashley E.A., Bers D.M., Robbins R.C., Longaker M.T., Wu J.C. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells // Cell Stem Cell. 2013. Vol. 12. № 1. P. 101–13.
  17. Liang P., Lan F., Lee A.S., Gong T., Sanchez-Freire V., Wang Y., Diecke S., Sallam K., Knowles J.W., Wang P.J., Nguyen P.K., Bers D.M., Robbins R.C., Wu J.C. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity // Circulation. 2013. Vol. 127. № 16. P. 1677–91.
  18. Lu J., Wei H., Wu J., Jamil M.F., Tan M.L., Adenan M.I., Wong P., Shim W. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes // PLoS One. 2014. Vol. 9. № 12. P. e115648.
  19. Awad M.M., Calkins H., Judge D.P. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy // Nat. Clin. Pract. Cardiovasc. Med. 2008. Vol. 5 № 5. P. 258–67.
  20. Caspi O., Huber I., Gepstein A., Arbel G., Maizels L., Boulos M., Gepstein L. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells // Circ. Cardiovasc. Genet. 2013. Vol. 6. № 6. P. 557–68.
  21. Fatima A., Dittmann S., Kaifeng S., Xu G., Lehmann M., Linke M., Zechner U., Hennies H. C., Stork I., Rosenkranz S., Farr M., Milting H., Hescheler J., Horstkotte D., Šarić T. Derivation of induced pluripotent stem (iPS) cells from a patient with an arrhythmogenic right ventricular cardiomyopathy (ARVC) // J. Stem. Cells. Regen. Med. 2010. Vol. 6. № 2. P. 97.
  22. Kim C., Wong J., Wen J., Wang S., Wang C., Spiering S., Kan N.G., Forcales S., Puri P.L., Leone T.C., Marine J.E., Calkins H., Kelly D.P., Judge D.P., Chen H.S. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs // Nature. 2013. Vol. 494. № 7435. P. 105–10.
  23. Hensley N., Dietrich J., Nyhan D., Mitter N., Yee M.S., Brady M. Hypertrophic cardiomyopathy: a review // Anesth. Analg. 2015. Vol. 120. № 3. P. 554–69.
  24. Houston B.A., Stevens G.R. Hypertrophic cardiomyopathy: a review // Clin. Med. Insights. Cardiol. 2014. Vol. 8. Suppl. 1. P. 53–65.
  25. Semsarian C., Ingles J., Maron M.S., , Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2015. Vol. 65. № 12. P. 1249–54.
  26. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., Yang L., Kaplan A.D., Adler E.D., Rozov R., Ge Y., Cohen N., Edelmann L.J., Chang B., Waghray A., Su J., Pardo S., Lichtenbelt K.D., Tartaglia M., Gelb B.D., Lemischka I.R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome // Nature. 2010. Vol. 465. № 7299. P. 808–12.
  27. Luk A., Ahn E., Soor G.S., Butany J. Dilated cardiomyopathy: a review // J. Clin. Pathol. 2009. Vol. 62. № 3. P. 219–25.
  28. Petretta M., Pirozzi F., Sasso L., Paglia A., Bonaduce D. Review and metaanalysis of the frequency of familial dilated cardiomyopathy // Am. J. Cardiol. 2011. Vol. 108. № 8. P. 1171–6.
  29. Hershberger R.E., Morales A., Siegfried J.D. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals // Genet. Med. 2010. Vol. 12. №11. P. 655–67.
  30. Siu C.W., Lee Y.K., Ho J.C., Lai W.H., Chan Y.C., Ng K.M., Wong L.Y., Au K.W., Lau Y.M., Zhang J., Lay K.W., Colman A., Tse H.F. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells // Aging (Albany NY). 2012. Vol. 4. № 11. P. 803–22.
  31. Palau F. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review) // Int. J. Mol. Med. 2001. Vol. 7. № 6. P. 581–9.
  32. Albano L.M., Nishioka S.A., Moyses R.L., Wagenführ J., Bertola D., Sugayama S.M., Chong A.K. Friedreich's ataxia: cardiac evaluation of 25 patients with clinical diagnosis and literature review // Arq. Bras. Cardiol. 2002. Vol. 78. № 5. P. 444–51.
  33. Bourke T., Keane D. Friedreich's Ataxia: a review from a cardiology perspective // Ir. J. Med. Sci. 2011. Vol. 180. № 4. P. 799–805.
  34. Hick A., Wattenhofer-Donze M., Chintawar S., Tropel P., Simard J.P., Vaucamps N., Gall D., Lambot L., André C., Reutenauer L., Rai M., Teletin M., Messaddeq N., Schiffmann S.N., Viville S., Pearson C.E., Pandolfo M., Puccio H. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia // Dis Model Mech. 2013. Vol. 6. № 3. P. 608–21.
  35. Reynolds S. Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach // J. Multidiscip. Health. 2015. Vol. 8. P. 345–58.
  36. Yen T.Y., Hwu W.L., Chien Y.H., Wu M.H., Lin M.T., Tsao L.Y., Hsieh W.S., Lee N.C. Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review // Eur. J. Pediatr. 2008. Vol. 167. № 8. P. 941–4.
  37. Dudek J., Cheng I.F., Balleininger M., Vazd F.M., Streckfuss-Bömekeb K., Hübscherb D., Vukotica M., Wandersd R.J.A., Rehlinga P., Guan K. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome // Stem Cell Res. 2013. Vol. 11. № 2. P. 806–19.
  38. Wang G., McCain M.L., Yang L., He A., Pasqualini F.S., Agarwal A., Yuan H., Jiang D., Zhang D., Zangi L., Geva J., Roberts A.E., Ma Q., Ding J., Chen J., Wang D.Z., Li K., Wang J., Wanders R.J., Kulik W., Vaz F.M., Laflamme M.A., Murry C.E., Chien K.R., Kelley R.I., Church G.M., Parker K.K., Pu W.T. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies // Nat. Med. 2014. Vol. 20. № 6. P. 616–23.
  39. Taglia A., Picillo E., D'Ambrosio P., Cecio M.R., Viggiano E., Politano L. Genetic counseling in Pompe disease // Acta Myol. 2011. Vol. 30. № 3. P. 179–81.
  40. Huang H.P., Chen P.H., Hwu W.L., Chuang C.Y., Chien Y.H., Stone L., Chien C.L., Li L.T., Chiang S.C., Chen H.F., Ho H.N., Chen C.H., Kuo H.C. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification // Hum. Mol. Genet. 2011. Vol. 20. № 24. P. 4851–64.
  41. Merla G., Brunetti-Pierri N., Piccolo P., Micale L., Loviglio M.N. Supravalvular aortic stenosis: elastin arteriopathy // Circ. Cardiovasc. Genet. 2012. Vol. 5 № 6. P. 692–6.
  42. Morris C.A. Genetic aspects of supravalvular aortic stenosis // Curr. Opin. Cardiol. 1998. Vol. 13. № 3. P. 214–9.
  43. Samanich J.M., Levin T.L., Berdon W.E. The clinical and genetic distinction between familial supravalvular aortic stenosis (Eisenberg syndrome) and Williams-Beuren syndrome // Pediatr. Radiol. 2012. Vol. 42. № 10. P. 1269.
  44. Urban Z., Riazi S., Seidl T.L., Katahira J., Smoot L.B., Chitayat D., Boyd C.D., Hinek A. Connection between elastin haploinsufficiency and increased cell proliferation in patients with supravalvular aortic stenosis and Williams-Beuren syndrome // Am. J. Hum. Genet. 2002. Vol. 71. № 1. P. 30–44.
  45. Ge X., Ren Y., Bartulos O., Lee M.Y., Yue Z., Kim K.Y., Li W., Amos P.J., Bozkulak E.C., Iyer A., Zheng W., Zhao H., Martin K.A., Kotton D.N., Tellides G., Park I.H., Yue L., Qyang Y. Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells // Circulation. 2012. Vol. 126. № 14. P. 1695–704.
  46. Kinnear C., Chang W.Y., Khattak S., Hinek A., Thompson T., de Carvalho Rodrigues D., Kennedy K., Mahmut N., Pasceri P., Stanford W.L., Ellis J., Mital S. Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells // Stem Cells Transl. Med. 2013. Vol. 2. № 1. P. 2–15.
  47. Communal C., Singh K., Pimentel D.R., Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway // Circulation. 1998. Vol. 98. № 13. P. 1329–34.
  48. Wu C.F., Bishopric N.H., Pratt R.E. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes // J. Biol. Chem. 1997. Vol. 272. № 23. P. 14860–6.